Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06931197 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Implementing a Contingency Management Program Addressing Methamphetamine Use for and With the People of Hawai'i

StatusWithdrawn
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Stopped Withdrawn before enrolling Sponsor's reason: The study never commenced. The funding went through as year 2 for NCT06532370 Show 8 more changesShow less
    • Lead sponsor: Queen's Medical Center to Queen's Medical Center
    • Enrollment target: estimated 20 to confirmed 0
    • Start date changed from estimate of Jan 1, 2026 to Apr 1, 2026
    • Primary completion date changed from estimate of Jul 31, 2026 to Sep 13, 2026
    • Eligibility criteria expanded, about 17 words
    • Secondary endpoints: details revised at 1 of 1 entry
    • Site details revised
    • Study title expanded, about 4 words
  2. Notable Start date: Aug 1, 2025 to Jan 1, 2026v3
  3. Notable Start date: Jul 1, 2025 to Aug 1, 2025
    • Primary and study completion dates: Jun 30, 2026 to Jul 31, 2026
    v2
  4. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This clinical trial is to implement contingency management (CM) as an intervention tool to address methamphetamine use and will be initiated during inpatient acute hospitalization in trauma injured patients. The goals are: * Gather effectiveness data on a CM program for participants in Hawaii who use methamphetamine during hospitalization and following discharge due to trauma injury * To assess participant perspectives on engaging with a CM program based at a Level 1 Trauma Center. Researches will assess both patient-reported and biologically-confirmed medium-term program effectiveness and conduct qualitative interviews with participants post-program. * To assess the rate of leaving against medical advice (AMA) and treatment completion in acute hospital setting in participants. * To assess the optimal timing of CM initiation for traumatically injured hospitalized patients by comparing patient outcomes (i.e. duration of CM participation and rates of CM program completion and providing negative urine samples) to NCT06532370 where CM was initiated after discharge from the hospital. For total of 12 weeks, participants will: * Be visited on Mondays/Thursdays or Tuesdays/Fridays by the research team to complete urine analysis during the hospitalization * Visit a follow up clinic up to 2 times per week on Mondays/Thursdays or Tuesdays/Fridays to complete urinalysis following discharge from the hospital * Complete Treatment Effectiveness Assessments at 6 and 12 weeks * Engage in qualitative interview at the end of the CM program
Trial Details
NCT Number NCT06931197
Lead Sponsor Queen's Medical Center
Conditions
(from sponsor)
Contingency Management, Methamphetamine Use Disorder
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov